Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Tax Provisions: 2009-2024

Historic Tax Provisions for Gyre Therapeutics (GYRE) over the last 8 years, with Dec 2024 value amounting to $6.3 million.

  • Gyre Therapeutics' Tax Provisions rose 57.64% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 32.92%. This contributed to the annual value of $6.3 million for FY2024, which is 32.38% down from last year.
  • As of FY2024, Gyre Therapeutics' Tax Provisions stood at $6.3 million, which was down 32.38% from $9.3 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Tax Provisions registered a high of $9.3 million during FY2023, and its lowest value of $6.0 million during FY2022.
  • Its 3-year average for Tax Provisions is $7.2 million, with a median of $6.3 million in 2024.
  • As far as peak fluctuations go, Gyre Therapeutics' Tax Provisions soared by 56.13% in 2023, and later plummeted by 32.38% in 2024.
  • Over the past 3 years, Gyre Therapeutics' Tax Provisions (Yearly) stood at $6.0 million in 2022, then skyrocketed by 56.13% to $9.3 million in 2023, then tumbled by 32.38% to $6.3 million in 2024.